These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 27061141

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery.
    Ewe A, Noske S, Karimov M, Aigner A.
    Pharmaceutics; 2019 Nov 12; 11(11):. PubMed ID: 31726756
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A.
    J Gene Med; 2010 Mar 12; 12(3):287-300. PubMed ID: 20052738
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery.
    Höbel S, Prinz R, Malek A, Urban-Klein B, Sitterberg J, Bakowsky U, Czubayko F, Aigner A.
    Eur J Pharm Biopharm; 2008 Sep 12; 70(1):29-41. PubMed ID: 18499413
    [Abstract] [Full Text] [Related]

  • 7. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo.
    Zhupanyn P, Ewe A, Büch T, Malek A, Rademacher P, Müller C, Reinert A, Jaimes Y, Aigner A.
    J Control Release; 2020 Mar 10; 319():63-76. PubMed ID: 31866504
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A.
    Toxicol Appl Pharmacol; 2009 Apr 01; 236(1):97-108. PubMed ID: 19371615
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The combined disulfide cross-linking and tyrosine-modification of very low molecular weight linear PEI synergistically enhances transfection efficacies and improves biocompatibility.
    Karimov M, Appelhans D, Ewe A, Aigner A.
    Eur J Pharm Biopharm; 2021 Apr 01; 161():56-65. PubMed ID: 33582186
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo.
    Höbel S, Aigner A.
    Methods Mol Biol; 2010 Apr 01; 623():283-97. PubMed ID: 20217558
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.